Snapshot from Sep 17, 2026 at 07:00 UTC. For live data and tracking: View Live
Business debt investment

SRX Global acquires CERo senior secured debt

Analysis based on 6 articles · First reported Aug 31, 2026 · Last updated Aug 31, 2026

Sentiment
10
Attention
2
Articles
6
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard

The investment provides CERo with additional capital to advance its clinical programs, potentially boosting its valuation and development prospects. For SRX Global, the secured debt investment aligns with its strategy of investing in high-conviction companies, potentially enhancing its portfolio returns.

Biotechnology Investment

SRX Global Inc., an AI-enabled investment platform, announced on August 31, 2026, that it has purchased senior secured debt in Coeptis Therapeutics Holdings, Inc., a cellular immunotherapy company developing engineered T cell therapeutics. The investment is intended to provide CERo with additional capital to accelerate its clinical programs, particularly the advancement of its lead candidate CER-1236 in the Phase 1 CERTAIN-T trial for hematologic malignancies. SRX Global's CEO, Alex Cunningham, highlighted the strategic fit and the clinical progress of CER-1236. CERo has treated six patients in the ongoing trial, with no dose-limiting toxicities observed in the most recent cohort, and has initiated the third planned cohort, which will include patients with myelodysplastic syndromes and myelofibrosis.

90 SRX Global purchased senior secured debt Coeptis Therapeutics Holdings
stock
CERo is the recipient of the debt investment, which provides additional capital to accelerate its clinical programs, particularly CER-1236. This funding is expected to support the advancement of its lead candidate and broader R&D efforts.
Importance 100.0 Sentiment 70.0
priv
SRX Global is the investor, purchasing senior secured debt in CERo, which aligns with its strategy of investing in high-conviction operating companies. This investment could provide SRX Global with potential returns and strategic benefits.
Importance 80.0 Sentiment 60.0
per
Alex Cunningham, CEO of SRX Global, announced the investment and expressed confidence in CERo's approach and clinical progress. His leadership is instrumental in executing SRX Global's investment strategy.
Importance 30.0 Sentiment 50.0
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.